Literature DB >> 19521782

Crystal structure transformations and dissolution studies of cimetidine-piroxicam coprecipitates and physical mixtures.

Vimon Tantishaiyakul1, Sarunyoo Songkro, Krit Suknuntha, Pattakarn Permkum, Pattawee Pipatwarakul.   

Abstract

We have recently demonstrated that coprecipitation of cimetidine (C) and piroxicam (P) at a mole ratio of 1:1 results in the transformation of the crystalline forms of both drugs to an amorphous state. In this study, coprecipitates and physical mixtures of cimetidine and piroxicam were further investigated at C/P mole ratios of 1:10, 1:5, 1:4, 1:2, 10:1, 20:1, 30:1, 40:1, and 52.5:1, the latter being the composition of a clinically used dosage. The physicochemical properties of these samples were examined using X-ray diffraction and Fourier transform infrared spectroscopy. Additionally, dissolution of piroxicam in the samples at C/P mole ratios of 10:1, 20:1, 30:1, 40:1, and 52.5:1 was investigated at pH 1.2 and pH 4. In coprecipitates with C/P mole ratios of 10:1, 20:1, 30:1, and 40:1, crystalline forms of both drugs were transformed to amorphous states. A mixture of an amorphous state and cimetidine crystalline form A was observed for the coprecipitate with a C/P mole ratio of 52.5:1. For the coprecipitates with C/P mole ratios of 1:2, 1:4, 1:5, and 1:10, cimetidine form A was transformed to form C, whereas piroxicam form II was modified to form I. It is interesting that small molecules, instead of polymers or solvents, can cause such crystal structure transformations. The dissolution of piroxicam at pH 4 is lower than that at pH 1.2. Additionally, the coprecipitates and physical mixtures with C/P mole ratios of 10:1, 20:1, 30:1, 40:1, and 52.5:1 demonstrate substantially higher dissolution of piroxicam compared to that of drug alone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19521782      PMCID: PMC2802155          DOI: 10.1208/s12249-009-9263-9

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  25 in total

Review 1.  Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system.

Authors:  Chi-Yuan Wu; Leslie Z Benet
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

2.  Generalization of a prototype intelligent hybrid system for hard gelatin capsule formulation development.

Authors:  Wendy I Wilson; Yun Peng; Larry L Augsburger
Journal:  AAPS PharmSciTech       Date:  2005-10-22       Impact factor: 3.246

3.  The in vitro effects of piroxicam and meloxicam on canine cell lines.

Authors:  C Knottenbelt; G Chambers; E Gault; D J Argyle
Journal:  J Small Anim Pract       Date:  2006-01       Impact factor: 1.522

4.  Use of drifts and PLS for the determination of polymorphs of piroxicam alone and in combination with pharmaceutical excipients: a technical note.

Authors:  Vimon Tantishaiyakul; Pattakarn Permkam; Krit Suknuntha
Journal:  AAPS PharmSciTech       Date:  2008-01-15       Impact factor: 3.246

5.  Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man.

Authors:  S A Said; A M Foda
Journal:  Arzneimittelforschung       Date:  1989-07

6.  Comparison of 200 mg cimetidine with multiple doses of antacid on extent and duration of rise in gastric pH in volunteers.

Authors:  A B Thomson; P Kirdeikis; L Zuk
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

Review 7.  Antiinflammatory drugs and gastric mucosal damage.

Authors:  E L Semble; W C Wu
Journal:  Semin Arthritis Rheum       Date:  1987-05       Impact factor: 5.532

8.  Application of differential scanning calorimetry to the study of solid drug dispersions.

Authors:  K H Kim; M J Frank; N L Henderson
Journal:  J Pharm Sci       Date:  1985-03       Impact factor: 3.534

Review 9.  Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (review).

Authors:  Florence Lefranc; Paul Yeaton; Jacques Brotchi; Robert Kiss
Journal:  Int J Oncol       Date:  2006-05       Impact factor: 5.650

10.  Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.

Authors:  Ekarat Jantratid; Sompol Prakongpan; Gordon L Amidon; Jennifer B Dressman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

View more
  4 in total

1.  Characterization of cimetidine-piroxicam coprecipitate interaction using experimental studies and molecular dynamic simulations.

Authors:  Vimon Tantishaiyakul; Krit Suknuntha; Visit Vao-Soongnern
Journal:  AAPS PharmSciTech       Date:  2010-05-29       Impact factor: 3.246

2.  Pharmaceutical Co-Crystals, Salts, and Co-Amorphous Systems: A Novel Opportunity of Hot Melt Extrusion.

Authors:  Sagar Narala; Dinesh Nyavanandi; Priyanka Srinivasan; Preethi Mandati; Suresh Bandari; Michael A Repka
Journal:  J Drug Deliv Sci Technol       Date:  2020-11-09       Impact factor: 3.981

3.  The function of oxybuprocaine: a parachute effect that sustains the supersaturated state of anhydrous piroxicam crystals.

Authors:  Momoko Fujita; Satoru Goto; Hitoshi Chatani; Yuta Otsuka; Yohsuke Shimada; Hiroshi Terada; Katsuyuki Inoo
Journal:  RSC Adv       Date:  2020-01-08       Impact factor: 4.036

4.  Amorphous solid dispersion formation via solvent granulation - A case study with ritonavir and lopinavir.

Authors:  Niraj S Trasi; Sonal Bhujbal; Qi Tony Zhou; Lynne S Taylor
Journal:  Int J Pharm X       Date:  2019-11-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.